Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
REGULATORY
MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
The Fiscal System Council submitted its recommendation paper for FY2019 budget formulations to Finance Minister Taro Aso on November 20, calling on the government to use economic evaluations when it makes go/no-go decisions on the reimbursement of drugs and other…
To read the full story
Related Article
- MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
- MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
- CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
- Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
- MOF Reiterates Drug Cost Optimization, but Makes No Fresh Proposal: Fiscal System Council
October 10, 2018
REGULATORY
- Daiichi Sankyo’s Enhertu Clears MHLW Panel, Conditional Nod Expected in March
February 27, 2020
- Rust in Needles in Sanofi’s ActHIB “Occurred Accidentally,” Supplies to Resume: MHLW
February 27, 2020
- Zolgensma Now in Line for Japan Approval in March, All Eyes Now Riveted on Price
February 27, 2020
- MHLW Orders Label Revisions for 9 Hep C Drugs
February 26, 2020
- Japan Plans to Reimburse Coronavirus Tests: Health Minister
February 26, 2020
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…